natgillin/translations-raw huggingface dataset:
A method for conveying in mould labels (IML), to a moulding machine such as an injection moulding machine that moulds items for example cups or lids, where the in mould labels will be integrated in the items, characterized in that the method comprises the following steps: supplying the in mould labels on a roll, semi-punching the in mould labels such that they remain attached to the roll via connection points or bridges, attaching the roll with the semi-punched in mould labels to an apparatus (1), rolling out the roll with the in mould labels in stages, passing the in mould labels through a tool (5), removing the in mould labels with a device which tears over the connection points or bridges that hold the in mould labels onto the roll and then transferring the in mould labels to the moulding machine. 
Postupak transportiranja predotisnutih polimernih spljoštenih objekata (IML), koje se primjerice proizvodi u tzv. flekso tiskarskom stroju i dodaje na valjku, stroju za lijevanje, poput injekcijskog tijeska, kojim se prave artikli poput šalica ili poklopaca, naznačen time što će se spljoštene objekte integrirati u artikle, poluprobijanjem spljoštenih objekata na takav način da ostaju pričvršćeni na valjak na spojnim točkama ili mostovima, gdje se zatim valjak sa spljoštenim objektima izvalja u stadijima, tako da spljošteni objekti prolaze kroz alat (5) s rupama (9) takvog oblika da odgovaraju obliku spljoštenog objekta, nakon čega se spljošteni objekt uklanja robotom koji upotrebljava vakuumsku sisaljku radi otkidanja mostova koji drže spljoštene objekte na valjku, te zatim prenosi spljoštene objekte do injekcijskog tijeska.
The formulation of claim 21, wherein the final concentration of the succinate buffer is 5 mM. 
Formulacija u skladu s patentnim zahtjevom 20, naznačena time što je pufer sukcinatni, u konačnoj koncentraciji od 5 mM.
Downstream of the sixth filter the mixture can be granulated, or be directly fed to a known line for producing multilayer (coextruded) slabs. 
Iza šestog filtra u smjeru odvijanja postupka, mješavina se može granulirati ili se može direktno voditi na poznatu liniju za proizvodnju višeslojnih (koekstrudiranih) ploča.
R4 is optionally substituted alkyl; 
R* je izborno supstituirani alkil;
The tool according to claim 1, wherein the inner region includes a central chamber, a cleaning fluid supply line is arranged at the centre of the chamber and the cleaning face, rotatable about a swivel, arms extend in radial direction from the cleaning fluid supply line, cleaning nozzles are arranged on the arms, directed inclined at an angle inwards at the surface to be cleaned, inside the chamber. 
Alat prema patentnom zahtjevu 1, naznačen time da ploha za čišćenje sadrži središnju komoru, cijev za opskrbu tekućine za čišćenje smještena je u centru središnje komore i površine za čišćenje, rotira se oko osi, krakovi se protežu u radijalnom smjeru od centralne rotirajuće cijevi za opskrbu, mlaznice za čišćenje su smještene na krakovima, iskošene su i usmjerene pod kutom na unutra prema površini koja se treba očistiti, unutar komore.
In one embodiment, the invention relates to a composition comprising at least 99.0% by weight of trans-(+)-A9-THC; in another embodiment, at least 99.0.0% by weight of trans-(+)-A9-THC; in another embodiment, at least 99.5.0% by weight of 
Postupak prema bilo kojem od zahtjeva 7 do 10, naznačen time da (+)-A*-tetrahidrokanabinol sadrži barem 95% težinski, poželjno barem 98% težinski i poželjnije barem 99% težinski trans-(-)-A*-tetrahidrokanabinola i trans-(+)- A?-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
Ch#N), wherein, in order to generate said data pseudo-streams (3c,3d), said splitting means (4) will: 
ChiHN), gdje, da bi se generirali navedeni pseudo-tokovi (3c,3d) podataka, navedena sredstva (4) za razdvajanje će:
Under the conditions of the fermentation process described, culturing in a 10-liter fermentor to produce IGF-I, there is an optimal G3P feed rate, per approximately 8-10 liters, in the preferred range of about 1-7 mmoles/hour, more preferably about 1-6 mmoles/hour, still more preferably about 2-6 mmoles/hour, yet more preferably about 2-5 mmoles/hour, and most preferably about 3-4 mmoles/hour. 
Postupak prema zahtjevu 11, naznačen time, da je brzina punjenja organofosfatom od oko 1 do 7 mmola po satu za svakih oko 8-10 litara i kultiviranje se odvija u 10-litarskoj napravi za fermentiranje, posebno je brzina punjenja organofosfatom od 2 do 6 mmola po satu za svakih oko 8-10 litara, još bolje kada je brzina punjenja organofosfatom od oko 3 do 4 mmola po satu za svakih oko 8-10 litara.
The pharmaceutical composition of claim 10, the vaccine of claim 23, or the peptide or polynucleotide of claim 24, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer; diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, upotreba u skladu s patentnim zahtjevom 9, 19 ili 22, ili cjepivo u skladu s patentnim zahtjevom 19 ili 21, naznačeni time što rak se bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, rak debelog crijeva, endometrioza, rak jednjaka, rak želuca, difuzni tip raka želuca, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, rak gušterače, rak prostate, karcinom bubrega, SCLC, tumor mekog tkiva i tumor testisa.
wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl, mono- and polyhalo-C1-3alkyloxy; heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazyl, pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each optionally substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl, mono- and polyhalo-C1-3alkyloxy; or an addition salt or a solvate thereof. 
pri čemu homoaril je fenil ili fenil supstituiran s jednim, dva ili tri supstituenta odabrana iz skupine koju čine halo, cijano, C1-3alkil, C1-3alkiloksi, mono- i polihalo-C1-3alkil, mono- i polihalo-C1-3alkiloksi; heteroaril je odabran iz skupine koju čine piridil, pirimidil, pirazil, piridazil, furanil, tienil, pirolil, pirazolil, imidazolil, triazolil, tiazolil, tiadiazolil, oksazolil, i oksadiazolil, svaki proizvoljno supstituiran s jednim, dva ili tri supstituenta odabrana iz skupine koju čine halo, cijano, C1-3alkil, C1-3alkiloksi, mono- i polihalo-C1-3alkil, mono- i polihalo-C1-3alkiloksi; ili njegova adicijska sol ili solvat.
A host organism containing a recombinant nucleic acid coding for a vitamin K reductase complex subunit 1 (VKORC1), and a recombinant nucleic acid coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism, wherein the host organism is a mammalian cell, wherein the secretion rate of the recombinantly expressed VKD protein is substantially increased when compared to the expression of the rVKD protein in a host organism which does not co-express recombinant VKORC1, and wherein the recombinant VKD protein is an anticoagulant or procoagulant blood factor. 
HR P20130028 T1 PATENTNI ZAHTJEVI Organizam domačina, naznačen time, da sadrži jednu rekombinantnu nukleinsku kiselinu, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORCI1) i jednu rekombinantnu nukleinsku kiselinu, koja kodira za vitamin K-ovisan protein (VKD), pri čemu su i rekombinantna VKORCI kao i rekombinantni VKD- protein eksprimirani u spomenutom organizmu domaćina, te je pritom količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećana u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira TVKORC1.
the pharmaceutical composition comprises dextran; 
(vi) farmaceutski sastav obuhvaća dekstran;
a binding domain capable of binding to the three fibronectin type III domains having seq ID:444 and the L2 domain having seq ID:445 of the extracellular domain of IGF-1R. 
vežuća domena, koja se može vezati na tri fibronektin tip III domene sa SEQ ID:444 i L2 domenu sa SEQ ID:445 izvanstanične domene IGF-1R.
The genetically modified cell of claim 3, wherein the donor sequence is integrated within any of the sequences of SEQ ID Nos. 
Genetski modificirana stanica prema patentnom zahtjevu 2, naznačena time što aberantan gen Hbb sadrži genomsku modifikaciju kod ili u blizini bilo koje od sekvenci prikazanih kao SEQ ID NOs.
VLP according to at least one of the above claims, wherein the VLP is composed of VP1 proteins of JC virus. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu se virusu slična čestica (VLP) primjenjuje oralno, parenteralno ili intravenozno.
A composition according to any preceding claim for treating an autoimmune disease. 
Sastav prema zahtjevu 11, naznačen time, da autoimuna bolest je multipla skleroza.
It is understood that a “radio-labeled” or “labeled compound” is a compound of Formula (I) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 125I, 35S and 82Br. 
Razumljivo je da "radiološki obilježen" ili "obilježen spoj" je spoj Formule (I) koji ima ugrađen barem jedan radionukleotid; u nekim oblicima radionukleotid je izabran iz skupine koja se sastoji od *H, '"C,!?I, *S i "Br.
accelerating movement, with a resilient element (90), of the at least one of the shoes toward the other of the shoes during a brake application cycle. 
ubrzavajuće kretanje, s elastičnim elementom (90), barem jedne papučice prema drugoj papučici tijekom ciklusa aktivacije kočnice.
A method for the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis encephalitis; pain; and reproductive disorders and skin inflammatory and fibrotic diseases in a subject in need thereof comprising administering to said subject an effective amount of a compound selected from the group consisting of 17a-Benzyl-3B-fluoropregnenolone, 17a-Benzyl-3B-benzyloxypregnenolone, 3B-Benzyloxy-17a-methylpregnenolone, 17a-Benzylpregnenolone, 3B-Methoxy-17a-methylpregnenolone, 17a-Allyl-3B-methoxypregnenolone or 17a-Benzyl-3B-methoxypregnenolone. 
Farmaceutski sastav koji obuhvaća tvar u skladu s patentnim zahtjevom 11 i farmaceutski prihvatljivi nosač. Tvar u skladu s patentnim zahtjevom 11, za uporabu u metodi liječenja ljudskog ili životinjskog tijela. Tvar u skladu s patentnim zahtjevom 11, za uporabu u liječenju patološkog stanja ili poremećaja izabranog iz grupe koja se sastoji od poremećaja mjehura ili gastriontestinalnih poremećaja, upalnih bolesti, kardiovaskularnih bolesti, nefropatija, glaukoma, spastičnosti, raka, osteoporoze, metaboličkih poremećaja, pretilosti, ovisnosti, loše navike, zlouporabe i poremećaja povezanih s relapsom, psihijatrijskih i neuroloških poremećaja, neurodegenerativnih poremećaja, autoimunog hepatitisa i encefalitisa, boli i reproduktivnih poremećaja i kožnih upalnih i fibroznih bolesti.
The process of Claim 1, where P is selected from t-butoxycarbonyl, trityl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, formyl, trimethylsilyl, and t-butyldimethylsilyl. 
[image] naznačen time, da P predstavlja amino-zaštitnu skupinu odabranu od t-butoksickrbonila, tritila, benziloksikarbonila, 9-fluoroenilmetoksikarbonila, formila i benzila; ili njihove soli.
a tip portion connected to the distal end of the body portion; 
vršni dio povezan s distalnim krajem tijela;
When the results from the two experiments are compared, the most diluted sample is clearly distinct from the other six samples (Figure 9). 
Kada se rezultati ova dva eksperimenta uspoređuju, najviše razrijeđeni uzorci su jasno različiti od drugih šest uzoraka (Slika 9).
A combination according to claim 9 wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) B2 agonists. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
16, there is shown another embodiment of a modular system for providing bicycles. 
900a-900d) 1 time se dobiva modularni sustav za ponudu bicikala.
A method for suppressing a viral infection, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound having the following structure: or a pharmaceutically acceptable salt or hydrate thereof; wherein the virus is selected from the group consisting of viruses of the orthomyxoviridae, bunyaviridae, flaviviridae, and filoviridae families. 
Spoj formule I: [image] naznačen time da A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, za primjenu u inhibiciji virusne RNK polimeraze izabrane iz grupe koja se sastoji od virusnih polimeraza orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae i coronaviridae.
The compound of formula (I) according to any one of the claims 1-4, and/or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixture, enantiomers, diasteromers, tautomers thereof, wherein R2 is C1-4 alkyl, preferably methyl and ethyl; and/or wherein R3 is H; and/or wherein m is 1. 
Spoj s formulom (I) prema bilo kojem od patentnih zahtjeva 1-4, i/ili njegova farmaceutski prihvatljiva sol, i/ili njegovi solvati, racemična smjesa, enantiomeri, dijasteromeri, tautomeri, naznačen time što R2 je C1-4 alkil, poželjno metil i etil; i/ili pri čemu R3 je H; i/ili pri čemu m je 1.
A composition according to claim 5 wherein the composition is buffered by an acetate/acetic acid, lactate/ lactic acid, or Glycin / HCl buffer. 
Pripravak u skladu sa zahtjevom 5, naznačen time, da je pripravak puferiran pomoću acetat/octena kiselina, laktat/mliječna kiselina ili Glicin/HCI pufera.
The method as claimed in claim 2, wherein the step of forming the tablet (C) by compression is carried out at a pressure (P) ranging from 1 bar to 5 bar. 
Postupak sukladno zahtjevu 3, pri čemu se kompresijski korak izvodi pod tlakom (P) opsega 1 bar do 5 bara, poželjno od oko 2.5 bara.
The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein R2 is a phenyl unsubstituted or substituted by one or two substituents each independently selected from C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, halogen and cyano; an unsubstituted pyrazolyl; an unsubstituted pyridin-2-onyl; an unsubstituted pyrrolidinyl; or an unsubstituted thiazolyl. 
Spoj ili farmaceutski prihvatljiva sol istog prema patentnom zahtjevu 1 gdje R2 je fenil nesupstituiran ili supstituiran sa jednim ili dva supstituenta svakim nezavisno odabranim od C14 alkil, C14 alkoksi, C14 haloalkil, halogen i cijano; nesupstituirani pirazolil; nesupstituirani piridin-2-onil; nesupstituirani pirolidinil; ili nesupstituirani tiazolil
The binder is selected from the group comprising acacia, microcrystalline cellulose, cellulosic solutions such as hydroxypropylmethylcellulose, gelatin solutions 10-20%, glucose solutions 20-50%, polyvinylpyrrolidone, starch paste 10-20%, sorbitol, tragacanth, polyethyleneglycol, maltodextrin, polymethacrylates and povydone, and mixtures thereof. 
Vezivo se odabire iz skupine koja sadrži akaciju, mikrokristaliničnu celulozu, otopine celuloze kao što je hidroksipropilmetilceluloza, želatinske 10-20%-tne otopine, 20-50%-tne otopine glukoze, polivinilpirolidon, 10-20%tna škrobna pasta, sorbitol, tragakant, polietilenglikol, maltodekstrin, polimetakrilati 1 povidon, i njihove smjese.
In another embodiment, the invention provides a method for treating a patient suffering from a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, disorders of the gastrointestinal system, angiogenesis, angiogenesis-dependent conditions and other diseases and disorders associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). 
Derivat pirazolin diona prema bilo kojem od zahtjeva od 1 do 9, za upotrebu u liječenju bolesti ili stanja izabranog od kardiovaskularnih poremećaja, respiratornih poremećaja, poremećaja metabolizma, kožnih poremećaja, koštanih poremećaja, neuroinflamatornih i/ili neurodegenerativnih poremećaja, bolesti bubrega, poremećaja reprodukcije, bolesti koje pogađaju oko i/ili očnu leću i/ili stanja koja pogađaju unutarnje uho, upalni poremećaji, bolesti jetra, bol, tumori, alergijski poremećaji, traume, sepse, hemoragični i anafilaktički šok, bolesti ili poremećaji gastrointestinalnog sustava, angiogeneze, stanja koja zavise od angiogeneze i drugih bolesti i/ili poremećaji koji su povezani s nikotinamid adenin dinukleotid fosfat (NADPH) oksidazom.
In certain embodiments, a VEGF/DLL4-binding agent (e.g., antibody) competes for specific binding to DLL4 with an antibody that comprises a heavy chain variable region comprising SEQ ID NO:9 SEQ ID NO:10, SEQ ID NO:58, or SEQ ID NO:64 and a light chain variable region comprising SEQ ID NO:12. 
(b) drugo varijabilno područje teškog lanca koje ima najmanje 90% identiteta sekvence od SEQ ID NO: 64, SEQ ID NO: 9, SEQ ID NO: 10 ili SEQ ID NO: 58; 1 (c) prvo i drugo varijabilno područje lakog lanca, koja imaju najmanje 90% identiteta sekvence od SEQ ID NO: 12.
The method as claimed in claim 2, wherein the method further comprises applying moisture on the powder based sub layer and thereafter applying heat in order to dry the powder based sub layer. 
Metoda u skladu sa patentnim zahtjevom 2, gdje metoda dalje sadrži korak nanošenja vlage na pod-sloj sa osnovom od praha (12) i zatim primjenu topline sa ciljem da se osuši pod sloj sa osnovom od praha (12).
The method according to Claim 3 is characterised by the fact that the remote measuring and control device (1) signals the fault of one broken conductor within the electrical MV line if one LV effective value of interphase voltage is U2 < 0,7 . 
Postupak prema patentnom zahtjevu 6, naznačen time da se greška vodiča u prekidu unutar električne SN linije signalizira ako jedna NN stvarna vrijednost međufaznog napona U2 <0,7.
The method of embodiment 5, wherein the step of determining whether an IMSI is appropriate is based on previously determined preferences for the subscribed device. 
Postupak prema zahtjevu 5, pri čemu je korak za određivanje da li je IMSI odgovarajući baziran na prethodno određenim preferencama pretplatničkog uređaja.
a gel former, and an organic solvent selected from the group consisting of C1-C10 alcohols, esters of C1-C10 alcohols with C1-C10 carboxylic acids, C3-C8 alkyl ketones, and mixtures thereof and comprising less than 5 wt.-% water for use in the treatment of actinic keratosis. 
C) tvar za formiranje gela, i d) organsko otapalo odabrano iz skupine koja se sastoji od Ci-C,, alkohola, estera C;-Cuo alkohola s C;-Ci9 karboksilnim kiselinama, C3-Cg alkilnih ketona i njihovih smjesa te sadrži manje od 5% vode za primjenu u liječenju aktinske keratoze .
1'- dissolving the preservatives in distilled water, adding an acidifying agent until obtaining a suitable pH so the polymers do not gel in the following step, 
' otapanja konzervansa u destiliranoj vodi, te dodavanja sredstva za zakiseljavanje dok se ne postigne pH između 2,5 i 3,5, tako da se polimeri ne želiraju u sljedećem koraku,
A combination of any one of claims 1-7 for use in the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose)polymerase (PARP). 
Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, stereoizomer ili tautomer, naznačen time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koje može biti poboljšano inhibicijom poli(ADP-riboza)polimeraze (PARP).
The process according to claim 6 for the manufacture of compound I 
Postupak prema zahtjevu 6 za proizvodnju spoja I
All formulations for oral administration should be in dosages suitable for such administration. 
Sve formulacije za oralnu primjenu trebaju biti u doziranjima pogodnim za takvu primjenu.
determining (S1190) the intra prediction mode of the prediction unit by comparing the prediction mode index with the three intra prediction modes of the MPM group if the mode group indicator does not indicate the MPM group, wherein if one of the left intra prediction mode and the above intra prediction mode is available, the MPM group is comprised of the available intra prediction mode and two additional intra prediction modes, and DC mode and planar mode are set as the two additional intra prediction modes, if the available intra prediction mode is a directional intra prediction mode. 
određivanje (S1190) intrapredikcijskog režima predikcijske jedinice usporedbom indeksa predikcijskog režima s tri intrapredikcijska režima iz MPM grupe ukoliko indikator grupe režima ne ukazuje na MPM grupu, gdje ukoliko je raspoloživ jedan od lijevog intrapredikcijskog režima i gornjeg intrapredikcijskog režima, MPM grupa je sastavljena od raspoloživog intrapredikcijskog režima i dva dodatna intrapredikcijska režima, i DC režim i planarni režim se postavljaju kao dva dodatna intrapredikcijska režima ukoliko je raspoloživi intrapredikcijski režim usmjereni intrapredikcijski režim.
The method of claim 17, wherein the endogenous mouse Vk gene segments have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. The method of claim 17, wherein the human Vλ and Jλ gene segments comprise at least 12 human Vλ gene segments. 
Miš prema patentnom zahtjevu 1, naznačen time, što miš sadrži: od 12 do 40 nepreuređenih segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca A (hV2) i najmanje jedan humani segment gena JA (hJA); 1 humanu međugensku sekvencu nukleinske kiseline VK-JK smještenu između 12 do 40 segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca i najmanje jedne sekvence nukleinske kiseline JA.
Ascorbic acid fatty acid esters are ascorbic acid acylated with single or multiple fatty acid groups, wherein the fatty acids typically have 8 to 24 carbon atoms, and their salts. 
Pripravak iz patentnog zahtjeva 2, naznačen time, da ester askorbinske kiseline ili njezina sol sadrži ester masne kiseline s 8 do 24 atoma ugljika.
No. 10/140,596 and WO 99/58253 illustrate in more detail several embodiments of a receiver/bottle arrangement 20 such that could be used with system 10 . 
U patentnoj prijavi Serial No, 10/140,596 i WO 99/58253 detaljnije je prikazano nekoliko sklopova nosač/boca 20 koji bi se mogli primijeniti sa sustavom 10.
a peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO: 288; 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78.